Protekt Therapeutics

Protekt Therapeutics Overview

Protekt Therapeutics is a biopharmaceutical company aiming to identify and develop a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimers disease and mild cognitive impairment. PKR is a stress and proapoptotic kinase that phosphorylates eIF2, a key protein in the translation machinery, and results in inhibition of protein synthesis and impaired memory consolidation. PKR is also activated during apoptosis, autophagy, neuroinflammation, and A peptide toxicity, which are prominent features of Alzheimer's Disease (AD). Therefore, PKR inhibition offers a novel and promising disease-modifying mechanism for modulating multiple key processes in AD and other neurodegenerative diseases. ProteKt Therapeutics was established in the FutuRx Incubator in December 2015 based on technology from Prof. Kobi Rosenblum's lab (Haifa University) and is now fully owned by Bukwang Pharmaceutical.

Cumulative Funding Raised Over Time ($)

Latest News

Jul 21, 2020 · www.globes.co.il

growth-positive

החברה שמצאה מנגנון חדש שעשוי לעכב אלצהיימר

Israeli company ProteKt Therapeutics is developing a new treatment for Alzheimers disease based on a mechanism called PKR. The company has developed a drug that inhibits the activity of PKR, which is released in the body during stress, and can cause a reduction in protein production in cells. The company has raised $3.6 million in a recent funding round from investors including Fonds de Solidarite and Bukwang Pharmaceutical, bringing its total funding to over $7 million.

Investment

Feb 6, 2020 · www.timesofisrael.com

growth-positive

Israeli startup hopes to battle Alzheimer's with enzyme-busting drug

Israeli startup ProteKt Therapeutics is developing a drug to treat early stages of Alzheimer’s by targeting an enzyme. The company has raised $3.6 million in funding from investors including Quebec’s Fonds de solidarité FTQ fund and Korean pharma firm Bukwang Pharmaceutical. ProteKt has identified a series of 150 small synthetic compounds that could help inhibit the enzyme and has shown their potential to improve cognition in lab tests. The funding will be used to further develop and improve the most effective molecule and conduct animal testing. ProteKt aims to prove that the compound can enter the brain and plans to undertake clinical trials in the future.

Investment

Nov 13, 2019 · en.globes.co.il

growth-positive

Israeli co ProteKt Therapeutics raises $3.6m

ProteKt Therapeutics, an Israeli biotech company, has signed a binding agreement for a $3.6 million equity financing round. The financing will be used to select a lead drug candidate molecule and validate its neurotherapeutic effects in vivo. The company also plans to initiate the clinical development of a related diagnostic assay for patient selection and treatment personalization. The funding will enable ProteKt Therapeutics to continue the development of novel therapies for neurodegenerative diseases, such as Alzheimers disease. The company aims to adopt a precision medicine approach and develop a patient selection diagnostic assay to increase the likelihood of effective treatment. The equity financing round was co-led by Fonds de Solidarité FTQ and Bukwang Pharmaceutical, along with existing investors FutuRx, OrbiMed, Johnson & Johnson Innovation - JJDC, Inc., Takeda Ventures, Inc., and RM Global Partners (RMGP) BioPharma Investment Fund.

Investment

May 18, 2017 · www.globes.co.il

growth-positive

RM Global to invest $30m in FutuRx biotech startups

US-based international investment bank RM Global is establishing a new venture capital fund that has already closed its first financing round of $30 million and will soon embark on a second financing round. The fund will invest exclusively in companies operating in Israels FutuRx incubator in Ness Ziona near Rehovot. The fund has raised money from financial and strategic investors, and hopes to raise additional tens of millions of dollars.

InvestmentPartners

Dec 15, 2015 · www.israel21c.org

growth-positive

Haifa team IDs activity of proteins linked to memory loss

A study by University of Haifa scientists has identified brain proteins associated with memory impairments in Alzheimers disease. The study also found that repairing this activity leads to an improvement in memory. The researchers hope to develop a drug that can delay the onset of cognitive symptoms. The study was published in the Journal of Neuroscience.

InvestmentPartners

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

Bar Kochva St 16, Bnei Brak, Israel

Photos & Videos

No files yet

Protekt Therapeutics Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info